IKP Stuttgart

What IKP Stuttgart does

The Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology (IKP) is a Stuttgart-based, non-profit clinical pharmacology research institute operating within the Bosch Health Campus under the Robert Bosch Foundation. Itself-described as the largest scientific research unit in clinical pharmacology in Germany, IKP focuses on pharmacogenomics, personalised medicine, and improving drug therapy outcomes, serving academic, clinical, and industry collaborators that require deep translational pharmacology expertise and analytical infrastructure.

IKP's operational structure rests on four core facilities — Chemical Analytics & Synthesis, Molecular Analytics, Biostatistics/Bioinformatics/Pharmacometrics/Artificial Intelligence, and Bioprinting/Biofabrication Technology — that provide the analytical and technological backbone for its research activities. On top of these facilities, the institute operates multiple disease-focused research groups spanning areas such as cancer, nephrology, and metabolic disease, and runs an early-phase clinical trial unit conducting studies in healthy participants. Together these constitute the platform through which IKP delivers translational pharmacology services and generates evidence on drug response and personalised dosing.

As a non-profit foundation-affiliated research institute, IKP's economic model is built on institutional funding from the Robert Bosch Foundation combined with third-party research funding, collaborative research agreements with academic and industry partners, and contract-based early-phase clinical trial activity. It is also embedded in the German NetPaeT national pharmacogenomics network, extending its reach beyond Stuttgart. The institute does not sell commercial products in the conventional sense; rather, it monetises scientific expertise and platform access through research outputs, collaborations, and trial services.

Name

IKP Stuttgart

Legal name

Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology

Website

https://ikp-stuttgart.de

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

IKP Stuttgart is a non-profit clinical pharmacology research institute within the Bosch Health Campus, focused on pharmacogenomics, personalised medicine, and early-phase clinical trials to improve drug therapy.

Ownership category

akta.pro rank

Product category

Clinical Pharmacology Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Other Scientific and Technical Consulting Services (541690), Other Scientific and Technical Consulting Services (54169)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro industry

PRIMARYHLAJAOAM

Global Health Research, Clinical Trials & Product Development Partnerships (PDPs)

Healthcare & Life Sciences/Public Health, Government & Regulators/Global Health Initiatives & Partnerships

SECONDARYHLAGACAK

Clinical Trial Pharmacy & IMP Management at Site

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Clinical Trial Services & Site Management (SMO)

SECONDARYHLAGACAG

Clinical Trial Monitoring Support (On-site/Remote)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Clinical Trial Services & Site Management (SMO)

Keywords

• Clinical pharmacology research
• Pharmacogenomics services
• Mass spectrometry analysis
• Drug therapy research
• Microphysiological tissue models

Headquarters

HQ city

Stuttgart

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Distribution channels3 records

Marketing channels3 records

Core offering

IKP Stuttgart (Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology) is a non-profit clinical pharmacology research institute that conducts research on improving drug therapy, with a focus on personalized medicine and pharmacogenomics. It operates shared Core Facilities (chemical and molecular analytics, biostatistics/bioinformatics, biofabrication) and specialized Research Groups, while also conducting early-phase clinical trials with healthy study participants.

Product overview

The Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology (IKP) is Germany's largest scientific research unit in clinical pharmacology. The institute operates as a research organization with two main structural components: Core Facilities (Chemical Analytics & Synthesis, Molecular Analytics, Biostatistics/Bioinformatics Pharmacometrics and AI, and Biofabrication) providing shared analytical and computational services; and Research Groups (including Clinical Pharmacogenomics & Digital Health, Microphysiological Tissue Models, Metabolism and Cancer Therapy, PharmacoOmics & Lymphoma, and the IKP Clinical Trial Unit) conducting focused research in personalized medicine, pharmacogenomics, and drug therapy optimization. The portfolio also includes Clinical Trials services for volunteer-based drug studies.

Differentiator

Problem solved

Functional benefit

Products and services

• Chemical Analytics & Synthesis (Core Facility)
• Molecular Analytics (Core Facility)
• Biostatistics/Bioinformatics, Pharmacometrics and Artificial Intelligence (Core Facility)
• Biofabrication (Core Facility)
• Microphysiological Tissue Models of Metabolic Disease (Research Group)
• Microphysiological Tissue Models of Solid Cancer and Microenvironment (Research Group)
• Clinical Pharmacogenomics & Digital Health (Research Group)
• Metabolism and Cancer Therapy (Research Group)
• Breast Cancer Recurrence and Clinical Translation (Research Group)
• PharmacoOmics & Lymphoma (Research Group)
• Secretome and Liquid Biopsy (Research Group)
• Advancing Precision Nephrology (Research Group)
• Drug Information & Patient Care (Research Group)
• IKP Clinical Trial Unit (Early-Phase Clinical Trials)
• German NetPaeT (German Network for Pharmacogenomics and Therapeutic Drug Monitoring)
• PGx Diagnostics (Research Group)
• Education & Training
• Translational Molecular Biology (Research Group)

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature4 records

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Mayo Clinic – Center for Individualized Medicine: Major US academic medical center with dedicated pharmacogenomics and individualized medicine programs. Comparable as a large, well-funded clinical pharmacology and individualized medicine research unit with clinical implementation focus.
• Max Delbrück Center for Molecular Medicine (MDC): Berlin-based biomedical research institute applying omics technologies and systems medicine to clinical questions. Comparable as a large German research institute combining molecular analytics, bioinformatics, and translational medicine.
• Fraunhofer Institute for Cell Therapy and Immunology (IZI): German applied research institute with GMP manufacturing, molecular analytics, and preclinical/clinical pharmacology capabilities. Comparable as a non-profit German research organization offering analytical and bio-fabrication services to external partners.
• Charité – Universitätsmedizin Berlin: One of Europe's largest university hospitals and a major German clinical pharmacology and pharmacogenomics research provider. Highly comparable because it operates in-house clinical trial units and pharmacogenomics programs in the same German regulatory environment as IKP.
• EMBL – European Molecular Biology Laboratory: Intergovernmental research organization in molecular life sciences with core facilities in genomics, bioinformatics, and structural biology. Comparable as a non-profit research institute offering shared core facility services and omics capabilities to external collaborators.

Direct peers

• Leiden University Medical Center (LUMC): Leads the European Ubiquitous Pharmacogenomics (U-PGx) consortium and operates a Center for Pharmacogenomics providing clinical implementation. Directly comparable as a large academic pharmacogenomics-to-clinic implementation institution with similar translational mission.
• St. Jude Children's Research Hospital – PG4KDS: Runs the PG4KDS clinical pharmacogenomics implementation program, one of the longest-running in pediatric oncology. Comparable as a research-driven PGx implementation institution with strong clinical trial integration.
• Vanderbilt University Medical Center – PREDICT Program: Operates one of the most mature clinical pharmacogenomics implementation programs (PREDICT) embedding PGx into routine care. Direct peer in clinical pharmacogenomics translation and digital health tooling.

Emerging players

• CN Bio Innovations: Commercial organ-on-chip / microphysiological system provider serving pharma drug discovery. Comparable to IKP's microphysiological tissue models capability, though operating as a commercial vendor rather than an academic research institute.
• Emulate Inc. Commercial organ-on-chip platform company whose products compete directly with IKP's research groups on microphysiological tissue models for drug research. Comparable via overlapping organ-on-chip technology for preclinical drug response studies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/ikp-stuttgart

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IKP Stuttgart